AC Immune SA (NASDAQ:ACIU - Free Report) - Research analysts at HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for shares of AC Immune in a research report issued on Thursday, May 1st. HC Wainwright analyst A. Fein now forecasts that the company will earn $0.12 per share for the year, down from their prior forecast of $0.16. HC Wainwright currently has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for AC Immune's current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for AC Immune's FY2028 earnings at $1.29 EPS and FY2029 earnings at $1.89 EPS.
Separately, StockNews.com cut AC Immune from a "buy" rating to a "hold" rating in a research report on Monday.
Read Our Latest Stock Analysis on ACIU
AC Immune Price Performance
Shares of NASDAQ ACIU traded up $0.02 during midday trading on Friday, reaching $1.64. 73,563 shares of the company traded hands, compared to its average volume of 176,896. The company has a market cap of $164.67 million, a price-to-earnings ratio of -3.57 and a beta of 1.62. AC Immune has a 52 week low of $1.43 and a 52 week high of $4.98. The stock has a 50-day moving average price of $1.88 and a 200 day moving average price of $2.54.
AC Immune (NASDAQ:ACIU - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. The firm had revenue of $1.12 million during the quarter, compared to the consensus estimate of $1.99 million.
Institutional Investors Weigh In On AC Immune
Large investors have recently made changes to their positions in the stock. Quinn Opportunity Partners LLC bought a new position in AC Immune in the fourth quarter valued at approximately $27,000. Two Sigma Advisers LP bought a new stake in shares of AC Immune in the fourth quarter worth $36,000. Boothbay Fund Management LLC acquired a new position in shares of AC Immune during the 4th quarter valued at $38,000. RPO LLC bought a new position in shares of AC Immune in the fourth quarter valued at $51,000. Finally, Jane Street Group LLC acquired a new position in AC Immune during the 4th quarter valued at about $66,000. Institutional investors own 51.36% of the company's stock.
About AC Immune
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
